Table 5.

Health impact projection of the number of people in each health outcome group for the advanced CTAP imaging and standard-of-care strategies for the 5 year period.

	Year 1	Year 2	Year 3	Year 4	Year 5	Total	Average
Annual health outcomes
Strategy 1: standard-of-care imaging
Lifetime QALYs of the cohort	8,839	9,467	9,803	10,369	10,790	49,267	9,853
Short term QALYs of the cohort	820	878	910	962	1,001	4,572	914
mRS 0-2	725	776	804	850	885	4,040	808
mRS 3-5	531	569	589	623	648	2,960	592
Deaths	250	268	277	293	305	1,393	279
Strategy 2: advanced imaging
Lifetime QALYs of the cohort	8,884	9,515	9,853	10,422	10,845	49,519	9,904
90-day QALYs of the cohort	827	886	917	970	1,009	4,609	922
mRS 0-2	737	789	817	864	899	4,106	821
mRS 3-5	519	556	576	609	634	2,894	579
Deaths	250	268	277	293	305	1,393	279
Incremental health impact
Lifetime QALYs of the cohort	45	48	50	53	55	252	50
Lifetime utility per person	0.0300	0.0300	0.0300	0.0300	0.0300		0.0300
90-day QALYs of the cohort	7	7	7	8	8	37	7
90-day utility per person	0.0045	0.0045	0.0044	0.0044	0.0043		0.0044
mRS 0-2	12	13	13	14	14	66	13
mRS 3-5	−12	−13	−13	−14	−14	−66	−13
Deaths	0	0	0	0	0	0	0
Relationship between costs and outcomes
Cost per functional dependence avoided	$78,441	$77,550	$80,303	$78,872	$82,073		$79,448
Cost per QALY gained	$20,837	$20,837	$20,837	$20,837	$20,837		$20,837

The incremental health impact of switching from the standard-of-care to the advanced CTAP imaging strategy is also shown.